Barclays PLC Has $3.23 Million Position in Zymeworks Inc. (NYSE:ZYME)

Barclays PLC raised its holdings in Zymeworks Inc. (NYSE:ZYME - Free Report) by 43.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 220,890 shares of the company's stock after buying an additional 66,506 shares during the quarter. Barclays PLC owned 0.32% of Zymeworks worth $3,234,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Sterling Capital Management LLC grew its stake in shares of Zymeworks by 781.5% in the fourth quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock worth $25,000 after acquiring an additional 1,524 shares during the last quarter. AlphaQuest LLC grew its position in Zymeworks by 480.2% in the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock worth $41,000 after purchasing an additional 2,324 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Zymeworks during the 4th quarter worth about $151,000. New York State Common Retirement Fund raised its position in shares of Zymeworks by 42.7% during the fourth quarter. New York State Common Retirement Fund now owns 13,371 shares of the company's stock valued at $196,000 after buying an additional 4,000 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in shares of Zymeworks by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 13,743 shares of the company's stock valued at $201,000 after buying an additional 2,216 shares during the period. 92.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. HC Wainwright upped their price target on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Monday, March 10th. Lifesci Capital assumed coverage on Zymeworks in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 target price for the company. Finally, Citigroup lifted their price target on shares of Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Zymeworks currently has an average rating of "Moderate Buy" and an average price target of $21.00.

Zymeworks Trading Up 0.6 %

Shares of Zymeworks stock traded up $0.08 during mid-day trading on Friday, reaching $12.96. 309,636 shares of the stock were exchanged, compared to its average volume of 611,498. The company has a market cap of $901.72 million, a price-to-earnings ratio of -8.64 and a beta of 1.24. Zymeworks Inc. has a fifty-two week low of $8.21 and a fifty-two week high of $17.70. The firm has a 50-day simple moving average of $12.01 and a 200 day simple moving average of $13.50.

Insider Transactions at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc bought 468,356 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were bought at an average price of $12.48 per share, for a total transaction of $5,845,082.88. Following the completion of the acquisition, the director now owns 16,802,141 shares of the company's stock, valued at approximately $209,690,719.68. This trade represents a 2.87 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders bought 1,350,347 shares of company stock valued at $16,137,499. Corporate insiders own 1.92% of the company's stock.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.